Plasma TGF-β₁, TIMP-1, MMP-1 and IL-18 as a combined biomarker of psoriasis activity

References

• Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators of Inflammation 2005; 24: 273–279
   Google Scholar
• Baran W, Szepietowski JC, Mazur G, Baran E. TGF-beta(1) gene polymorphism in psoriasis vulgaris. Cytokine 2007; 38: 8–11
   PubMed Web of Science ®Google Scholar
• Cai JP, Falanga V, Taylor JR, Chin YH. Transforming growth factor-beta receptor binding and function are decreased in psoriatic dermal endothelium. Journal of Investigative Dermatology 1996; 106: 225–231
   Google Scholar
• Choi CP, Kim YI, Lee JW, Lee MH. The effect of narrowband ultraviolet B on the expression of matrix metalloproteinase-1, transforming growth factor-beta1 and type I collagen in human skin fibroblasts. Clinical & Experimental Dermatology 2007; 32: 180–185
   Google Scholar
• Companjen AR, Van der Velden VH, Vooys A, Debets R, Benner R, Prens EP. Human keratinocytes are major producers of IL-18: predominant expression of the unprocessed form. European Cytokine Network 2000; 11: 383–390
   PubMed Web of Science ®Google Scholar
• Companjen A, Van der Wel L, Van der Fits L, Laman J, Prens E. Elevated interleukin-18 protein expression in early active and progressive plaque-type psoriatic lesions. European Cytokine Network 2004; 15: 210–216
   PubMed Web of Science ®Google Scholar
• Flisiak I, Chodynicka B, Porebski P, Flisiak R. Association between psoriasis severity and transforming growth factor beta1 and beta2 in plasma and scales from psoriatic lesions. Cytokine 2002; 19: 121–125
   PubMed Web of Science ®Google Scholar
• Flisiak I, Porebski P, Flisiak R, Chodynicka B. Plasma-transforming growth factor beta1 as a biomarker of psoriasis activity and treatment efficiency. Biomarkers 2003; 8: 437–443
   PubMed Web of Science ®Google Scholar
• Flisiak I, Mysliwiec H, Chodynicka B. Effect of psoriasis treatment on plasma concentrations of metalloproteinase-1 and tissue inhibitor of metalloproteinases-1. Journal of European Academy of Dermatology & Venereology 2005; 19: 418–421
   PubMedGoogle Scholar
• Flisiak I, Porebski P, Chodynicka B. Effect of psoriasis activity on metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in plasma and lesional scales. Acta Dermato-venereologica 2006a; 86: 17–21
   PubMedGoogle Scholar
• Flisiak I, Klepacki A, Chodynicka B. Plasma and scale levels of interleukin 18 in comparison with other possible clinical and laboratory biomarkers of psoriasis activity. Biomarkers 2006b; 11: 194–200
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978; 157: 238–244
   PubMedGoogle Scholar
• Furue M, Kato M, Nakamura K, Nashiro K, Kikuchi K, Okochi H, Miyazono K, Tamaki K. Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma. International Journal of Cancer 1997; 71: 505–509
   PubMedGoogle Scholar
• Gillespie MT, Horwood NJ. Interleukin-18: perspectives on the newest interleukin. Cytokine and Growth Factors Review 1998; 9: 109–116
   PubMedGoogle Scholar
• Kanda N, Shimizu T, Tada Y, Watanabe S. IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. European Journal of Immunology 2007; 37: 338–350
   PubMed Web of Science ®Google Scholar
• Kane CJ, Knapp AM, Mansbridge JN, Hanawalt PC. Transforming growth factor-beta 1 localization in normal and psoriatic epidermal keratinocytes in situ. Journal of Cell Physiology 1990; 144: 144–150
   PubMed Web of Science ®Google Scholar
• Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. Journal of the American Academy of Dermatology 2002; 46: 1–23
   PubMed Web of Science ®Google Scholar
• Leivo T, Leivo I, Kariniemi AL, Keski-Oja J, Virtanen I. Down-regulation of transforming growth factor-beta receptors I and II is seen in lesional but not non-lesional psoriatic epidermis. British Journal of Dermatology 1998; 138: 57–62
   PubMed Web of Science ®Google Scholar
• Mee JB, Alam Y, Groves RW. Human keratinocytes constitutively produce but do not process interleukin-18. British Journal of Dermatology 2000; 143: 330–336
   PubMed Web of Science ®Google Scholar
• Myers A, Lakey R, Cawston TE, Kay LJ, Walker DJ. Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblings. Rheumatology 2004; 43: 272–276
   Google Scholar
• Naik SM, Cannon G, Burbach GJ, Singh SR, Swerlick RA, Wilcox JN, Ansel JC, Caughman SW. Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with pro-inflammatory mediators and dinitrochlorobenzene. Journal of Investigative Dermatology 1999; 113: 766–772
   PubMed Web of Science ®Google Scholar
• Ohta Y, Hamada Y, Katsuoka K. Expression of IL-18 in psoriasis. Archives of Dermatological Research 2001; 293: 334–342
   PubMed Web of Science ®Google Scholar
• Oyama N, Iwatsuki K, Satoh M, Akiba H, Kaneko F. Dermal fibroblasts are one of the therapeutic targets for topical application of 1alpha,25-dihydroxyvitamin D3: the possible involvement of transforming growth factor-beta induction. British Journal of Dermatology 2000; 143: 1140–1148
   PubMed Web of Science ®Google Scholar
• Park HJ, Kim HJ, Lee JH, Lee JY, Cho BK, Kang JS, Kang H, Yang Y, Cho DH. Corticotropin releasing hormone (CRH) downregulates interleukin-18 expression in human HaCaT keratinocytes by activation of p38 mitogen-activated protein kinase (MAPK) pathway. Journal of Investigative Dermatology 2005; 124: 751–755
   PubMed Web of Science ®Google Scholar
• Simonetti O, Lucarini G, Goteri G, Zizzi A, Biagini G, Lo Muzio L, Offidani A. VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study. International Journal of Immunopathology & Pharmacology 2006; 19: 751–760
   PubMed Web of Science ®Google Scholar
• Singer AJ, Clark RAF. Cutaneous wound healing. New England Journal of Medicine 1999; 341: 738–746
   PubMed Web of Science ®Google Scholar
• Wang XJ, Greenhalgh DA, Bickenbach JR, Jiang A, Bundman DS, Krieg T, Derynck R, Roop DR. Expression of a dominant-negative type II transforming growth factor beta (TGFbeta) receptor in the epidermis of transgenic mice blocks TGFbeta mediated growth inhibition. Proceedings of the National Academy of Sciences U S A 1997; 94: 2386–2391
   PubMed Web of Science ®Google Scholar
• Wataya-Kaneda M, Hashimoto K, Kato M, Miyazono K, Yoshikawa K. Differential localization of TGF-(beta precursor isotypes in psoriatic human skin. Journal of Dermatological Science 1996; 11: 183–188
   PubMed Web of Science ®Google Scholar
• Wittmann M, Purwar R, Hartmann C, Gutzmer R, Werfel T. Human keratinocytes respond to interleukin-18: implication for the course of chronic inflammatory skin diseases. Journal of Investigative Dermatology 2005; 124: 1225–1233
   PubMed Web of Science ®Google Scholar